Staff Time and Motion Assessment for Administration of Erythropoiesis-Stimulating Agents: A Two-Phase Pilot Study in Clinical Oncology Practices
| Autor: | Ze Cong, Sanatan Shreay, Jason C. Legg, Arletta van Breda, Patricia K. Corey-Lisle, John F. Reitan |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Male
medicine.medical_specialty Time Factors Office Visits Cost-Benefit Analysis Personnel Staffing and Scheduling Antineoplastic Agents Pilot Projects Workload Medical Oncology Phase (combat) Drug Administration Schedule Pharmacotherapy Nursing Cost Savings hemic and lymphatic diseases Humans Medicine Pharmacology (medical) Prospective Studies Original Research Article Dosing Intensive care medicine Aged Retrospective Studies Analysis of Variance Myelosuppressive Chemotherapy Cost–benefit analysis business.industry Anemia Retrospective cohort study Health Care Costs General Medicine Middle Aged Cross-Sectional Studies Models Economic Time and Motion Studies Concomitant Hematinics Erythropoiesis Female business |
| Zdroj: | Clinical Drug Investigation |
| ISSN: | 1173-2563 |
| DOI: | 10.1007/s40261-013-0078-9 |
| Popis: | Background Erythropoiesis-stimulating agents (ESAs) are used for the management of anaemia in patients with non-myeloid malignancies where anaemia is due to the effect of concomitant myelosuppressive chemotherapy. Assessing the impact of different ESA dosing regimens on office staff time and projected labour costs is an important component of understanding the potential for optimization of oncology practice efficiencies. Objectives A two-phase study was conducted to evaluate staff time and labour costs directly associated with ESA administration in real-world oncology practice settings among cancer patients undergoing chemotherapy. The objective of Phase 1 was to determine the mean staff time required for the process of ESA administration in patients with anaemia due to concomitantly administered chemotherapy. The objective of Phase 2 was to quantify and compare the mean staff time and mean labour costs of ESA administered once weekly (qw) with ESA once every 3 weeks (q3w) over an entire course of chemotherapy. Methods Phase 1 was a prospective, cross-sectional time and motion study conducted in six private oncology practices in the US based on nine steps associated with ESA administration. Using findings from Phase 1, Phase 2 was conducted as a retrospective chart review to collect data on the number and types of visits in two private oncology practices for patients receiving a complete course of myelosuppressive chemotherapy. Results In Phase 1, the mean total time that clinic staff spent on ESA administration was 23.2 min for patient visits that included chemotherapy administration (nchemo = 37) and 21.5 min when only ESA was administered (nESAonly = 36). In Phase 2, the mean duration of treatment was significantly longer for q3w than qw (53.84 days for qw vs. 113.38 for q3w, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|